Amneal Pharmaceuticals Inc (FRA:2DT)
€ 7.25 -0.05 (-0.68%) Market Cap: 2.31 Bil Enterprise Value: 4.84 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

Amneal Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

Mar 13, 2019 / 05:35PM GMT
Release Date Price: €10.67 (+3.19%)
Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

Good afternoon. Continuing the session for the day. My name is Balaji from Barclays. And so we have with us today the management team from Amneal, including -- sorry, all right, there we go. So we have Rob Stewart, President and CEO; Paul Bisaro, Executive Chairman; and Todd Branning, SVP -- Senior Vice President and CFO. Gentlemen, thank you so much for taking the time out today. So the session will be in the form of a fireside chat, and our Q&As will be later on in the breakout session. And so before I launch into the sound of Q&As that we've discussed, Rob, would you like to kickstart off with some overview and comments.

Robert A. Stewart
Amneal Pharmaceuticals, Inc. - President, CEO & Director

Sure. First off, thank you for those attending here in person, as well as those that have dialed in via the webcast. I appreciate the time and the opportunity to meet with all of you. Summing up, 2018 was a transformational year for the company. We were starting with the Impax-Amneal deal

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot